培美曲塞联合顺铂治疗复发性晚期非小细胞肺癌45例

The Pemetrexed Combined with Cisplatin in the Treatment of 45 Patients with Recurrent Advanced Non-Small Cell Lung Cancer

目的探讨培美曲塞联合顺铂治疗复发性晚期非小细胞肺癌（NSCLC）的疗效及毒副反应。方法 45例经病理学确诊的复发性晚期NSCLC接受化疗：培美曲塞500 mg/m2,d1,静脉滴注;顺铂30 mg/m2,d1~3,静脉滴注,21 d为1个周期。2个周期后评价疗效及毒副反应。结果 45例中,CR 0例、PR 23例、NC 9例、PD 13例,总有效率51.1%。主要毒副反应为骨髓抑制、胃肠道反应和脱发。结论培美曲塞联合顺铂治疗复发性晚期NSCLC疗效确切,毒副反应可耐受。

Objective To investigate the efficacy and toxicities of pemetrexed combined with cisplatin in the treatment of recurrent advanced non-small cell lung cancer（NSCLC）.Methods All the 45 patients with pathologically confirmed recurrent advanced NSCLC received chemotherapy： pemetrexed 500 mg/m2,d1,intravenous infusion;cisplatin 30 mg/m2,d1-3,intravenous infusion,21 days were 1 cycle.The efficacy and toxicities were evaluated after 2 cycles of chemotherapy.Results Of all the 45 cases,CR was observed in 0 case,PR in 23 cases,NC in 9 cases,PD in 13 cases,and the response rate was 51.1%.The main toxicities were marrow suppression,gastrointestinal reaction and alopecia.Conclusion Pemetrexed combined with cisplatin is effective for recurrent advanced NSCLC,and the toxicities can be tolerated.